Skip to main content
. Author manuscript; available in PMC: 2010 Sep 1.
Published in final edited form as: Circ Cardiovasc Imaging. 2009 Jul 21;2(5):373–381. doi: 10.1161/CIRCIMAGING.108.843227

Figure 4.

Figure 4

The fractional net gain in glucose utilization uptake rate in untreated (ZDF), Metformin-treated (ZDF+MET) and Rosiglitazone-treated (ZDF+ROSI) ZDF rats at week 14 (W14) and week 19 (W14). Note: Y-axis is in logarithmic scale. *, denotes that the treatment is significantly better than no treatment; †, denotes that the Rosiglitazone treatment is significantly better than Metformin treatment. A P<0.05 was considered significant. All resulted are presented as mean ± 1 SD.